Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

被引:0
|
作者
Engel-Nitz, Nicole M. [1 ]
Johnson, Michael P. [1 ]
Bunner, Scott H. [1 ]
Ryan, Kellie J. [2 ]
机构
[1] Optum, 11000 Opt Cir,MN101-E300, Eden Prairie, MN 55344 USA
[2] AstraZeneca, Gaithersburg, MD USA
来源
关键词
NIVOLUMAB; DOCETAXEL;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer in the United States. Immunotherapies and cytotoxic chemotherapies used to treat advanced NSCLC carry a substantial risk of adverse events (AEs), but real-world data on the incidence and costs associated with the unique AE profiles of these treatments are sparse. OBJECTIVE: To examine the AE incidence and costs among patients initiating non-driver mutation-targeted first-line therapy for metastatic NSCLC (mNSCLC) in clinical practice. METHODS: This was a retrospective administrative claims study conducted among commercial and Medicare Advantage health plan members who initiated first-line, nontargeted systemic anti-NSCLC therapy between January 1, 2008, and February 28, 2018. Patients were assigned to mutually exclusive treatment cohorts (cytotoxic chemotherapy [CHEM], immuno-oncology agents [IO], or immuno-oncology + cytotoxic chemotherapy [IO-CHEM]) and were observed from the index date (start of first-line therapy) through the earliest of health plan disenrollment, death, or March 31, 2018. AE incidence rates and associated health care costs were measured from the index date through the earliest of the start of a new therapy, 180 days after the end of first-line therapy, or the end of the study period. The factors influencing whether patients incurred high AE-related health care costs were assessed using multivariable models adjusted for patient demographic and clinical characteristics. RESULTS: The final study population (mean [SD] age 68.6 [9.5] years, 53.9% male) included 8,818 in the CHEM cohort, 482 in the 10 cohort, and 412 in the IO-CHEM cohort. Overall, 74.4% had at least 1 AE during follow-up. The AE incidence rate was lowest for the 10 cohort, with incidence rate ratios (95% CI) of 1.4 (1.3-1.6) for the CHEM cohort and 1.4 (1.2-1.6) for the IO-CHEM cohort. Mean AE-related costs were lowest for the 10 cohort ($16,319) and highest for the CHEM cohort ($23,009; P< 0.001). In the multivariable analysis, the odds of incurring any AE costs were similar for the IO and IO-CHEM cohorts compared with the CHEM cohort (OR = 0.82; P=0.135 and OR= 0.98; P=0.888, respectively). Among patients who incurred AE costs, those in the 10 cohort were less likely than those in the CHEM cohort to have high costs (OR =0.60; P=0.030); the difference between the IO-CHEM and CHEM cohorts was not statistically significant. CONCLUSIONS: Among real-world patients initiating nontargeted first-line therapy for mNSCLC, those receiving immunotherapy experienced fewer AEs and had lower total AE-related costs than those treated with cytotoxic chemotherapy. Immunotherapy-treated patients were no more likely than chemotherapy-treated patients to incur AE-related costs and were less likely to have high AE costs if they incurred any at all. These findings indicate that immunotherapy-related AEs are not a differentiating factor in cost of care for this patient population in clinical practice. Copyright(C) 2020, Academy of Managed Care Pharmacy. All rights reserved.
引用
收藏
页码:729 / 740
页数:12
相关论文
共 50 条
  • [1] Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer†
    Byfield, Stacey DaCosta
    Chastek, Benjamin
    Korrer, Stephanie
    Horstman, Thomas
    Malin, Jennifer
    Newcomer, Lee
    [J]. CANCER INVESTIGATION, 2020, 38 (10) : 608 - 617
  • [2] Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small cell lung cancer
    Hsu, Grace G.
    MacKay, Eric
    Scheuer, Nicolas
    Ramagopalan, Sreeram, V
    [J]. IMMUNOTHERAPY, 2021, 13 (18) : 1453 - 1456
  • [3] Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting.
    De Castro, Javier
    Campos Balea, Begona
    Perez Parente, Diego
    Polito, Letizia
    Lawrance, Marcus
    Ruiz Gracia, Pedro
    Adler, Leah
    Marina Arroyo, Marta
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [5] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    [J]. Current Oncology Reports, 2021, 23
  • [6] Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
    Danesi, Valentina
    Massa, Ilaria
    Foca, Flavia
    Delmonte, Angelo
    Crino, Lucio
    Bronte, Giuseppe
    Ragonesi, Maria
    Maltoni, Roberta
    Manunta, Silvia
    Cravero, Paola
    Andrikou, Kalliopi
    Priano, Ilaria
    Balzi, William
    Gentili, Nicola
    Burke, Thomas
    Altini, Mattia
    [J]. CANCERS, 2022, 14 (18)
  • [7] Real-world experience with afatinib as first-line treatment in advanced non-small cell lung cancer in a university hospital
    Jang, Taewon
    Kim, Jaehoon
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [8] Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
    Pelicon, Veronika
    Cufer, Tanja
    Knez, Lea
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
    Kim, Y.
    Sun, J.
    Park, K.
    Park, S. E.
    Lee, S.
    Ahn, M.
    Ahn, J. S.
    Lim, S. W.
    Lee, H.
    Cho, J. H.
    Kim, H. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [10] COSTS OF CARE FOR FIRST-LINE (1L) TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A REAL-WORLD CLAIMS ANALYSIS
    Kish, Jonathan
    Chopra, Dhruv
    Liassou, Djibril
    Lubinga, Solomon
    Hartman, John
    Feinberg, Bruce
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A437 - A438